deaths (OS)

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib plus capecitabine
neratinib plus capecitabine vs. lapatinib plus capecitabine 2 -11%